Comparative effectiveness of fenfluramine versus cannabidiol in their licensed indications for the treatment of seizures in Dravet Syndrome: a systematic review and network meta-analysis

W Linley, M Schwenkglenks, N Hawkins, T Toward
doi: https://doi.org/10.1101/2022.07.01.22277155

Article Information

doi 
https://doi.org/10.1101/2022.07.01.22277155
History 
  • July 2, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. W Linley1,*,
  2. M Schwenkglenks2,
  3. N Hawkins3 and
  4. T Toward1
  1. 1Zogenix International ltd, maidenhead, UK
  2. 2Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland
  3. 3Visible Analytics Ltd, Oxford, UK
  1. ↵*Corresponding author: wlinley{at}zogenix.com
Back to top
Posted July 02, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Comparative effectiveness of fenfluramine versus cannabidiol in their licensed indications for the treatment of seizures in Dravet Syndrome: a systematic review and network meta-analysis
W Linley, M Schwenkglenks, N Hawkins, T Toward
medRxiv 2022.07.01.22277155; doi: https://doi.org/10.1101/2022.07.01.22277155
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area